Deletion of 3(p14p23) in secondary erythroleukemia arising in long-term survivors of small cell lung cancer

Jacqueline Whang-peng, Elaine C. Lee, John D. Minna, Martin D. Abeloff, Edward C. Bradley, Robert C. Young, Dan L. Longo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Cytogenetic studies were done on the leukemia cells of two patients with small cell lung cancer (SCLC) who developed erythroleukemia (acute non-lymphocytic leukemia, French-American-British M6) after combined modality chemotherapy and radiotherapy for their lung cancer. Surprisingly, both erythroleukemias exhibited the del(3)(pl4p23) predominantly found in SCLC. In four other patients who had secondary erythroleukemias associated with other cancers, no deletions of 3p were found. These findings could be accounted for by one of three possible mechanisms: (a) an inherited recessive gene (anti-oncogene or tumor suppressor gene) in this region of 3p was uncovered by the combined modality therapy, (b) an inherited predisposition to damage of both chromosomes at 3pl4 leads to SCLC and erythroleukemia after exposure to carcinogens and/orchemotherapy-radiotherapy, or (c) the finding of lineage specificity for the 3p deletion with the presence of the 3p deletion in SCLC and erythroleukemia suggests a common bone marrow precursor. [J Natl Cancer Inst 1988;80:1253-1255].

Original languageEnglish
Pages (from-to)1253-1255
Number of pages3
JournalJournal of the National Cancer Institute
Volume80
Issue number15
DOIs
Publication statusPublished - May 5 1988
Externally publishedYes

Fingerprint

Leukemia, Erythroblastic, Acute
Small Cell Lung Carcinoma
Survivors
Tumor Suppressor Genes
Radiotherapy
Recessive Genes
Combined Modality Therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytogenetics
Carcinogens
Lung Neoplasms
Neoplasms
Leukemia
Chromosomes
Bone Marrow
Drug Therapy
Monosomy 3p Chromosome 3

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Deletion of 3(p14p23) in secondary erythroleukemia arising in long-term survivors of small cell lung cancer. / Whang-peng, Jacqueline; Lee, Elaine C.; Minna, John D.; Abeloff, Martin D.; Bradley, Edward C.; Young, Robert C.; Longo, Dan L.

In: Journal of the National Cancer Institute, Vol. 80, No. 15, 05.05.1988, p. 1253-1255.

Research output: Contribution to journalArticle

Whang-peng, Jacqueline ; Lee, Elaine C. ; Minna, John D. ; Abeloff, Martin D. ; Bradley, Edward C. ; Young, Robert C. ; Longo, Dan L. / Deletion of 3(p14p23) in secondary erythroleukemia arising in long-term survivors of small cell lung cancer. In: Journal of the National Cancer Institute. 1988 ; Vol. 80, No. 15. pp. 1253-1255.
@article{3090f8bc7b924d29bfc1ce9e4f9b415d,
title = "Deletion of 3(p14p23) in secondary erythroleukemia arising in long-term survivors of small cell lung cancer",
abstract = "Cytogenetic studies were done on the leukemia cells of two patients with small cell lung cancer (SCLC) who developed erythroleukemia (acute non-lymphocytic leukemia, French-American-British M6) after combined modality chemotherapy and radiotherapy for their lung cancer. Surprisingly, both erythroleukemias exhibited the del(3)(pl4p23) predominantly found in SCLC. In four other patients who had secondary erythroleukemias associated with other cancers, no deletions of 3p were found. These findings could be accounted for by one of three possible mechanisms: (a) an inherited recessive gene (anti-oncogene or tumor suppressor gene) in this region of 3p was uncovered by the combined modality therapy, (b) an inherited predisposition to damage of both chromosomes at 3pl4 leads to SCLC and erythroleukemia after exposure to carcinogens and/orchemotherapy-radiotherapy, or (c) the finding of lineage specificity for the 3p deletion with the presence of the 3p deletion in SCLC and erythroleukemia suggests a common bone marrow precursor. [J Natl Cancer Inst 1988;80:1253-1255].",
author = "Jacqueline Whang-peng and Lee, {Elaine C.} and Minna, {John D.} and Abeloff, {Martin D.} and Bradley, {Edward C.} and Young, {Robert C.} and Longo, {Dan L.}",
year = "1988",
month = "5",
day = "5",
doi = "10.1093/jnci/80.15.1253",
language = "English",
volume = "80",
pages = "1253--1255",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Deletion of 3(p14p23) in secondary erythroleukemia arising in long-term survivors of small cell lung cancer

AU - Whang-peng, Jacqueline

AU - Lee, Elaine C.

AU - Minna, John D.

AU - Abeloff, Martin D.

AU - Bradley, Edward C.

AU - Young, Robert C.

AU - Longo, Dan L.

PY - 1988/5/5

Y1 - 1988/5/5

N2 - Cytogenetic studies were done on the leukemia cells of two patients with small cell lung cancer (SCLC) who developed erythroleukemia (acute non-lymphocytic leukemia, French-American-British M6) after combined modality chemotherapy and radiotherapy for their lung cancer. Surprisingly, both erythroleukemias exhibited the del(3)(pl4p23) predominantly found in SCLC. In four other patients who had secondary erythroleukemias associated with other cancers, no deletions of 3p were found. These findings could be accounted for by one of three possible mechanisms: (a) an inherited recessive gene (anti-oncogene or tumor suppressor gene) in this region of 3p was uncovered by the combined modality therapy, (b) an inherited predisposition to damage of both chromosomes at 3pl4 leads to SCLC and erythroleukemia after exposure to carcinogens and/orchemotherapy-radiotherapy, or (c) the finding of lineage specificity for the 3p deletion with the presence of the 3p deletion in SCLC and erythroleukemia suggests a common bone marrow precursor. [J Natl Cancer Inst 1988;80:1253-1255].

AB - Cytogenetic studies were done on the leukemia cells of two patients with small cell lung cancer (SCLC) who developed erythroleukemia (acute non-lymphocytic leukemia, French-American-British M6) after combined modality chemotherapy and radiotherapy for their lung cancer. Surprisingly, both erythroleukemias exhibited the del(3)(pl4p23) predominantly found in SCLC. In four other patients who had secondary erythroleukemias associated with other cancers, no deletions of 3p were found. These findings could be accounted for by one of three possible mechanisms: (a) an inherited recessive gene (anti-oncogene or tumor suppressor gene) in this region of 3p was uncovered by the combined modality therapy, (b) an inherited predisposition to damage of both chromosomes at 3pl4 leads to SCLC and erythroleukemia after exposure to carcinogens and/orchemotherapy-radiotherapy, or (c) the finding of lineage specificity for the 3p deletion with the presence of the 3p deletion in SCLC and erythroleukemia suggests a common bone marrow precursor. [J Natl Cancer Inst 1988;80:1253-1255].

UR - http://www.scopus.com/inward/record.url?scp=0023737282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023737282&partnerID=8YFLogxK

U2 - 10.1093/jnci/80.15.1253

DO - 10.1093/jnci/80.15.1253

M3 - Article

VL - 80

SP - 1253

EP - 1255

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 15

ER -